Yantai Lannacheng Biotechnology Co.,Ltd.
- Biotech or pharma, therapeutic R&D
Lannacheng (LNC) is a joint venture between Dongcheng Pharmaceutical, a leader in China’s nuclear medicine industry, and Professor Xiaoyuan (Shawn) Chen, a world-renowned expert in molecular imaging and nanomedicine.
We focus on developing first-in-class, integrated theranostic radiopharmaceuticals for oncology. Our pipeline covers a broad range of targets including PSMA, FAP, SSTR2, integrin αvβ3 and more, using small molecules, peptides, and antibodies to address prostate cancer, gliomas, neuroendocrine tumors, and other solid tumors. Our FAP-targeted agents are globally competitive, with several candidates under regulatory review in China and the U.S., and clinical trials ongoing worldwide. Backed by Dongcheng’s end-to-end nuclear medicine capabilities—from radionuclide production to manufacturing and commercialization—LNC is rapidly advancing innovation in the field.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}